- About ACRO
- ACRO Updates
- Policy Views
- Meetings + Events
- Media Center
- Contact Us
Mission Statement: ACRO and its members advocate on a global basis for safe, ethical, high-quality medical research so patients can benefit from the development of new treatments and therapies. Our members are dedicated to helping their clients bring efficiency, innovation and value to the clinical research process.
The Association of Clinical Research Organizations (ACRO) represents the world's leading clinical research organizations (CROs). Our members provide specialized services that are integral to the development of drugs, biologics and medical devices. ACRO advances clinical outsourcing to improve the quality, efficiency and safety of biomedical research. Each year, ACRO’s members conduct thousands of clinical trials and provide related drug development services in more than 115 countries while ensuring the safety of nearly 2 million research participants.
Since our founding in 2002, ACRO has been committed to strengthening public understanding and confidence in clinical research and to highlighting CRO expertise in all aspects of the clinical research enterprise. ACRO represents the CRO industry globally to pharmaceutical, biotech and medical device companies, regulators and legislators, peer associations, academic organizations, patient groups, the media and the public.
ACRO is a leading voice for safe and ethical clinical trials, working with stakeholders globally to explore new paradigms for research and development and to promote a better and more efficient clinical trial process. The association looks to demonstrate the strategic value of clinical outsourcing and the important contribution CROs make as partners in the development of new medicines and new treatments.
ACRO is especially interested in issues such as the globalization of clinical trials, HIT and privacy, comparative effectiveness research, conflicts of interest, clinical trial participation, safety and ethics in clinical research, and a host of global regulatory issues.